

PARTICIPANTS

Lajos Geczi

Department of Medicine C and Clinical Pharmacology,
National Institute of Oncology, Budapest - Hungary

Chris Harrison

Christie Hospital NHS Foundation Trust, Manchester - UK

Miklos Kasler

National Institute of Oncology, Budapest - Hungary

Jozsef Lovey

National Institute of Oncology, Budapest - Hungary

Electra D. Paskett

Assoc. Director for Population Science, College of Public
Health, Ohio – U.S.

Marco Pierotti

Fondazione nazionale Cancer Institute Milan - Italy

François Radvanyi

Institut Curie - Paris - France

Jorge S. Reis-Filho

The Breakthrough Breast Cancer Research Centre, London -
UK

Ulrik Ringborg

Karolinska University Hospital and Institute, Stockholm -
Sweden

Milena Sant

EUROCARE5 P.I., Analytical Epidemiology, INT, Milan -
Italy

Thomas Tursz

Gustav Roussy Institute -France

Marc J. van de Vijver

Academisch Medisch Centrum - Dept. of Pathology,
Amsterdam - The Netherlands

Wim van Harten

The Netherlands Cancer Institute, Amsterdam - The
Netherlands

Piret Veerus

EUROCHIP -3 Work Package on Cancer Rehabilitation,
National Institute of Health, Tallin – Estonia

Christopher Wild

International Agency for Research on Cancer, Lyon - France

Maja Zakelj

National Cancer Registry, Institute of Oncology Ljubljana -
Slovenia

AIMS

The conference topics are part of the actions and policies on cancer prevention and control currently being promoted by the European Union, within the framework of the European Partnership Action Against Cancer, and by other major International Organisations, such as the WHO within its 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Non-Communicable Diseases.

VENUE

Hotel Mercure Budapest Buda

Krisztina Korut 41-43 1013 BUDAPEST

Phone: (+36)1/4888100; E-mail:

H1688@accor.com

Web-site: <http://www.mercure.com/gb/hotel-1688-mercure-budapest-buda/index.shtml>

SECRETARIATS

OEI - EEIG

Rue d'Egmont 11, B -1000 Brussels, Belgium

Tel: +32 2 512 01 46 · Email: oei@oei.eu ·

<http://www.oei.eu>

Contact person: *Claudio Lombardo*

National Institute of Oncology

Ráth György u. 7-9, H – 1122 Budapest, Hungary

Tel: +36 1 2248600; Email: lovey@oncol.hu

Contact person: *Jozsef Lovey*



OEI 2010 SCIENTIFIC CONFERENCE

“MOLECULAR AND EPIDEMIOLOGICAL APPROACHES TO CANCER CONTROL”



BUDAPEST
18TH JUNE 2010

**In collaboration with: National Institute of
Oncology – Budapest**

**SCIENTIFIC PROGRAMME
JUNE, 18TH**

Morning Session

- 8.30 Registration
- 9.00 Welcome by the authorities
Miklos Kasler and Marco A. Pierotti

Keynote lectures

- 9.30 Two-way translational research: from basic science to the clinic and to the population
Christopher Wild
- 10.00 BRCA1 and BRCA2 cancers: from pathology to tailored therapies
Jorge S. Reis-Filho

10.30 Coffee Break

**SESSION 1: ORGANIZING CCCs TO GET
CANCER CONTROL**

Chair: Wim van Harten

- 11.00 State of the art concerning the organization of a CCC in U.S.
Electra D. Paskett
- 11.30 Quality leadership and competence development in CCC's
Chris Harrison
- 12.00 Translating operations management techniques and improving performance
Wim van Harten

12.30 Lunch

**SCIENTIFIC PROGRAMME
JUNE, 18TH**

Afternoon Session

**SESSION 2: MOLECULAR APPROACHES
FOR CANCER CONTROL**

**Chairpersons: Marc J. van de Vijver and
Lajos Geczi**

- 14.00 Current state and future perspectives of targeted therapies
Lajos Geczi
- 14.30 Molecular changes in urothelial malignancies
Francois Radvanyi
- 15.00 Molecular pathology of breast cancer
Marc J. van de Vijver

15.00 Coffee Break

**SESSION 3: EPIDEMIOLOGICAL
APPROACHES FOR CANCER CONTROL**

Chair: Ulrik Ringborg and Jozsef Lovey

- 16.00 The burden of Cancer in Europe
Maja Zakelj
- 16.30 Cancer Survival in Europe
Milena Sant
- 17.00 Cancer Rehabilitation in Europe
Piret Veerus

**SCIENTIFIC PROGRAMME
JUNE, 18TH**

- 17.30 A comprehensive view of clinical data registries.

Jozsef Lovey

- 18.00 Development of personalized cancer medicine – the role of patient data registries and bio-repositories with special attention to the relation between molecular data and the classical patient registries

Thomas Tursz

CONCLUSIONS

Marco A. Pierotti